{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:32:43Z","timestamp":1786735963741,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pathol Microbiol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/ijpm.ijpm_664_19","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T07:13:31Z","timestamp":1587107611000},"page":"214","source":"Crossref","is-referenced-by-count":7,"title":["HER-2\/neu over expression in gall bladder adenocarcinoma: A quest for potential therapeutic target"],"prefix":"10.4103","volume":"63","author":[{"given":"Puja","family":"Sakhuja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragya","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushik","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahajad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AnilK","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0377-4929.282708-1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/0377-4929.282708-2","unstructured":"The Globocan Cancer Observatory. Available from: http:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/39-All-cancers-fact-sheet.pdf. [Last accessed on 2019 Apr 10]."},{"key":"key-10.4103\/0377-4929.282708-3","unstructured":"CAP guidelines. Available from: https:\/\/documents.cap.org\/protocols\/cp-gastric-HER2biomarker17-1001. [Last accessed on 2019 Apr 10]."},{"key":"key-10.4103\/0377-4929.282708-4","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.3748\/wjg.v22.i35.7926","article-title":"HER2 aberrations and heterogeneity in cancers of the digestive system: Implication for pathologists and gastroenterologists","author":"Fusco","year":"2016","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/0377-4929.282708-5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-015-0155-z","article-title":"HER 2\/neu- directed therapy for biliary tract cancer","author":"Javle","year":"2015","journal-title":"J Hematol Oncol"},{"key":"key-10.4103\/0377-4929.282708-6","first-page":"221","article-title":"HER receptor Family: Novel candidate for targeted therapy for gall bladder and extrahepatic bile duct cancer","author":"Kawamoto","year":"2007","journal-title":"Gastrointest Cancer Res"},{"key":"key-10.4103\/0377-4929.282708-7","first-page":"3903","article-title":"Expression of human epidermal growth factor receptor (Her 2\/neu) and proliferative marker Ki-67: Association with clinicopathological parameters in gallbladder carcinoma","author":"Pujani","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"key-10.4103\/0377-4929.282708-8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1471-2407-6-126","article-title":"Preliminary study of p53 and c-erbB2 expression in gall bladder cancer in Indian patients","author":"Chaube","year":"2006","journal-title":"BMC Cancer"},{"key":"key-10.4103\/0377-4929.282708-9","first-page":"10","article-title":"Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma","author":"Doval","year":"2014","journal-title":"J Carcinog","ISSN":"https:\/\/id.crossref.org\/issn\/1477-3163","issn-type":"print"},{"key":"key-10.4103\/0377-4929.282708-10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0377-4929.94862","article-title":"Role of C-erbB2 expression in gall bladder cancer","author":"Kumari","year":"2012","journal-title":"Indian J Pathol Microbiol","ISSN":"https:\/\/id.crossref.org\/issn\/0377-4929","issn-type":"print"},{"key":"key-10.4103\/0377-4929.282708-11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2011.198","article-title":"HER2 testing in gastric cancer: A practical approach","author":"Ruschoff","year":"2012","journal-title":"Mod Pathol"},{"key":"key-10.4103\/0377-4929.282708-12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ng.3030","article-title":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway","author":"Li","year":"2014","journal-title":"Nat Genet"},{"key":"key-10.4103\/0377-4929.282708-13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 expression status in diverse cancers: Review of results from 37,992 patients","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"key-10.4103\/0377-4929.282708-14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.humpath.2009.10.002","article-title":"Epidermal growth factor receptor and HER-2\/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder","author":"Shafizadeh","year":"2010","journal-title":"Hum Pathol"},{"key":"key-10.4103\/0377-4929.282708-15","first-page":"42","article-title":"Overexpression of the HER2\/neu gene: A new therapeutic possibility for patients with advanced gallbladder cancer","author":"Roa","year":"2014","journal-title":"Gastrointest Cancer Res"},{"key":"key-10.4103\/0377-4929.282708-16","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s12253-014-9847-x","article-title":"Progostic value of increased HER 2 expression in cancer of pancreas and biliary tract","author":"Ata","year":"2015","journal-title":"Pathol Oncol Res"},{"key":"key-10.4103\/0377-4929.282708-17","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000450999","article-title":"Prognostic significance of HER-2 and p53 expression in gallbladder carcinoma in North Indian patients","author":"Singh","year":"2016","journal-title":"Oncology"},{"key":"key-10.4103\/0377-4929.282708-18","first-page":"1679","article-title":"Expression of p21(Waf1\/Cip1), p57(Kip2) and HER2\/neu in patients with gallbladder cancer","author":"Puhalla","year":"2007","journal-title":"Anticancer Res"},{"key":"key-10.4103\/0377-4929.282708-19","first-page":"815","article-title":"Gallbladder cancers rarely overexpress HER-2\/neu, demonstrated by Hercep test","author":"Matsuyama","year":"2004","journal-title":"Oncol Rep"},{"key":"key-10.4103\/0377-4929.282708-20","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.3748\/wjg.v18.i11.1208","article-title":"Expression of HER2 and bradykinin B1 receptors in precursor lesions of gall bladder carcinoma","author":"Toledo","year":"2012","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/0377-4929.282708-21","first-page":"1127","article-title":"Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas","author":"Kim","year":"2001","journal-title":"Oncol Rep"},{"key":"key-10.4103\/0377-4929.282708-22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trial","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"key-10.4103\/0377-4929.282708-23","doi-asserted-by":"crossref","first-page":"58007","DOI":"10.18632\/oncotarget.11157","article-title":"Therapeutic implication of HER2 in advanced biliary tract cancer","author":"Nam","year":"2016","journal-title":"Oncotarget"},{"key":"key-10.4103\/0377-4929.282708-24","first-page":"7","article-title":"HER2 as a therapeutic target in gallbladder cancer\u2014aye or nay?","author":"Lam","year":"2016","journal-title":"Transl Cancer Res"}],"container-title":["Indian Journal of Pathology and Microbiology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:35:32Z","timestamp":1786732532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJPM.IJPM_664_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"alternative-id":["282708"],"URL":"https:\/\/doi.org\/10.4103\/ijpm.ijpm_664_19","relation":{},"ISSN":["0377-4929"],"issn-type":[{"value":"0377-4929","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}